Needham & Company LLC Reaffirms “Buy” Rating for Immuneering (NASDAQ:IMRX)

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reiterated by equities research analysts at Needham & Company LLC in a report released on Monday,Benzinga reports. They currently have a $11.00 price objective on the stock. Needham & Company LLC’s target price suggests a potential upside of 106.38% from the company’s current price.

A number of other research analysts have also recently commented on IMRX. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research report on Thursday, November 13th. Finally, Wall Street Zen raised shares of Immuneering from a “sell” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Immuneering has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Up 7.0%

Shares of NASDAQ:IMRX opened at $5.33 on Monday. The company’s 50 day moving average price is $5.22 and its two-hundred day moving average price is $6.12. Immuneering has a 12-month low of $1.10 and a 12-month high of $10.08. The firm has a market cap of $344.16 million, a PE ratio of -3.86 and a beta of 0.46.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, March 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.13. On average, research analysts expect that Immuneering will post -1.86 EPS for the current year.

Insider Activity

In related news, Director Thomas J. Schall purchased 21,645 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were bought at an average cost of $4.67 per share, with a total value of $101,082.15. Following the acquisition, the director owned 74,530 shares of the company’s stock, valued at $348,055.10. This trade represents a 40.93% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Peter Feinberg acquired 20,000 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were bought at an average price of $4.35 per share, with a total value of $87,000.00. Following the completion of the transaction, the director owned 135,441 shares in the company, valued at $589,168.35. This represents a 17.32% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 51,819 shares of company stock valued at $234,472. Insiders own 22.90% of the company’s stock.

Institutional Trading of Immuneering

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its stake in shares of Immuneering by 2.0% during the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after buying an additional 4,458 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Immuneering in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Immuneering in the 3rd quarter valued at $35,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Immuneering during the 3rd quarter valued at $35,000. Finally, Southport Management L.L.C. grew its position in Immuneering by 1.8% during the 4th quarter. Southport Management L.L.C. now owns 277,501 shares of the company’s stock worth $1,826,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.